Trial · NCT07910266
Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza Vaccination
NCT07910266, Phase 4, Recruiting, University of Missouri-Columbia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza Vaccination. Trials, record NCT07910266. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910266
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza Vaccination
- NCT number
- NCT07910266
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 220 participants, estimated
- Lead sponsor
- University of Missouri-Columbia
- Conditions
- Immunology
- Interventions
- Egg-Based Inactivated Influenza Vaccine, Cell-Based Inactivated Influenza Vaccine
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers at 1 Month After the Second Vaccination | Before the first vaccination and 1 month after the second vaccination. | Hemagglutination inhibition (HAI) antibody titers against the prespecified influenza vaccine strains will be measured in serum samples using the HAI assay. Changes in HAI antibody geometric mean titers from baseline before the first vaccination to 1 month after the second vaccination will be compared among participants receiving four vaccination regimens: egg-egg, egg-cell, cell-egg, and cell-cell. |
| Secondary | Change from Baseline in Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers at 1 Month After the First Vaccination | Before the first vaccination and 1 month after the first vaccination. | Hemagglutination inhibition (HAI) antibody titers against the prespecified influenza vaccine strains will be measured in serum samples using the HAI assay. Changes in HAI antibody geometric mean titers from baseline before the first vaccination to 1 month after the first vaccination will be compared among participants in the four vaccination regimens, as appropriate to their assigned vaccination sequence. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers17
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910266
GET https://conductscience.org/api/trials/v1/NCT07910266/registered